Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of BAX for outcome prediction in gastrointestinal malignancies.
Pietrantonio F, Biondani P, Ciurlia E, Fanetti G, Tessari A, Bertarelli G, Bossi I, Musella V, Melotti F, Di Bartolomeo M, Valvo F, Pellegrinelli A, Milione M, Perrone F, de Braud F. Pietrantonio F, et al. Among authors: bossi i. Med Oncol. 2013;30(3):610. doi: 10.1007/s12032-013-0610-z. Epub 2013 May 23. Med Oncol. 2013. PMID: 23700226 Review.
A review on biomarkers for prediction of treatment outcome in gastric cancer.
Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M. Pietrantonio F, et al. Among authors: bossi i. Anticancer Res. 2013 Apr;33(4):1257-66. Anticancer Res. 2013. PMID: 23564763 Free article. Review.
TP53 mutations in advanced colorectal cancer: the dark side of the moon.
Pietrantonio F, Biondani P, Perrone F, Di Bartolomeo M, Pacifici M, Milione M, Melotti F, Maggi C, Montemurro G, Bossi I, Mariani L, de Braud F. Pietrantonio F, et al. Among authors: bossi i. Oncology. 2014;86(5-6):289-94. doi: 10.1159/000360088. Epub 2014 Jun 7. Oncology. 2014. PMID: 24924261
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Pietrantonio F, Perrone F, de Braud F, Castano A, Maggi C, Bossi I, Gevorgyan A, Biondani P, Pacifici M, Busico A, Gariboldi M, Festinese F, Tamborini E, Di Bartolomeo M. Pietrantonio F, et al. Among authors: bossi i. Ann Oncol. 2014 Feb;25(2):404-8. doi: 10.1093/annonc/mdt547. Epub 2013 Dec 29. Ann Oncol. 2014. PMID: 24379162 Free article. Clinical Trial.
Toward the molecular dissection of peritoneal pseudomyxoma.
Pietrantonio F, Perrone F, Mennitto A, Gleeson EM, Milione M, Tamborini E, Busico A, Settanni G, Berenato R, Caporale M, Morano F, Bossi I, Pellegrinelli A, Di Bartolomeo M, de Braud F, Baratti D, Bowne WB, Kusamura S, Deraco M. Pietrantonio F, et al. Among authors: bossi i. Ann Oncol. 2016 Nov;27(11):2097-2103. doi: 10.1093/annonc/mdw314. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502722 Free article.
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.
Pietrantonio F, Maggi C, Di Bartolomeo M, Facciorusso MG, Perrone F, Testi A, Iacovelli R, Miceli R, Bossi I, Leone G, Milione M, Pelosi G, de Braud F. Pietrantonio F, et al. Among authors: bossi i. PLoS One. 2014 Apr 1;9(4):e92147. doi: 10.1371/journal.pone.0092147. eCollection 2014. PLoS One. 2014. PMID: 24691006 Free PMC article.
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.
Pietrantonio F, Maggi C, Fanetti G, Iacovelli R, Di Bartolomeo M, Ricchini F, Deraco M, Perrone F, Baratti D, Kusamura S, Tamborini E, Castano A, Consonni PV, Bossi I, Gavazzi C, Milione M, Pelosi G, de Braud F. Pietrantonio F, et al. Among authors: bossi i. Oncologist. 2014 Aug;19(8):845-50. doi: 10.1634/theoncologist.2014-0106. Epub 2014 Jun 20. Oncologist. 2014. PMID: 24951608 Free PMC article.
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S. Pietrantonio F, et al. Among authors: bossi i. Eur J Cancer. 2015 Mar;51(5):587-94. doi: 10.1016/j.ejca.2015.01.054. Epub 2015 Feb 9. Eur J Cancer. 2015. PMID: 25673558 Review.
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
Musella V, Pietrantonio F, Di Buduo E, Iacovelli R, Martinetti A, Sottotetti E, Bossi I, Maggi C, Di Bartolomeo M, de Braud F, Daidone MG, Cappelletti V. Musella V, et al. Among authors: bossi i. Int J Cancer. 2015 Sep 15;137(6):1467-74. doi: 10.1002/ijc.29493. Epub 2015 Mar 4. Int J Cancer. 2015. PMID: 25704501 Free article.
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Pietrantonio F, de Braud F, Milione M, Maggi C, Iacovelli R, Dotti KF, Perrone F, Tamborini E, Caporale M, Berenato R, Leone G, Pellegrinelli A, Bossi I, Festinese F, Federici S, Di Bartolomeo M. Pietrantonio F, et al. Among authors: bossi i. Target Oncol. 2016 Jun;11(3):337-43. doi: 10.1007/s11523-015-0397-2. Target Oncol. 2016. PMID: 26538496
91 results